Literature DB >> 33498980

Liraglutide-Induced Hepatotoxicity.

Yaakov Maor1, David Ergaz2, Stephen D H Malnick3, Ehud Melzer1, Manuela G Neuman4.   

Abstract

A 52-year-old woman with a BMI of 31.2 kg/m2 was treated with the glucagon-like peptide 1 (GLP-1) agonist liraglutide as part of her weight-reduction program. Following this, she developed an idiosyncratic drug-related liver injury (IDILI). Advances in noninvasive techniques enabled this diagnosis to be established. By employing easily quantifiable methods based on serum biomarkers, we could explore a wide variety of endpoints in assessing personalized DILI. In addition, we can test endpoints that are associated with the drug's mechanism of action. Personalized medicine and therapeutic pharmacovigilance of incretin-based hypoglycemic agents are needed to ensure the safety of patients.

Entities:  

Keywords:  drug-induced liver injury; liraglutide-induced immune hepatitis; lymphocyte toxicity assay; personalized medicine

Year:  2021        PMID： 33498980      PMCID： PMC7911918          DOI： 10.3390/biomedicines9020106

Source DB:  PubMed          Journal:  Biomedicines        ISSN： 2227-9059


  23 in total

Review 1.  Autoantibody-negative autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2011-12-21       Impact factor: 3.199

2.  Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial.

Authors:  Michael A Nauck; Marie Louise Muus Ghorbani; Eskil Kreiner; Hans A Saevereid; John B Buse
Journal:  Diabetes Care       Date:  2019-08-09       Impact factor: 19.112

3.  All-cause mortality in patients with diabetes under glucagon-like peptide-1 agonists: A population-based, open cohort study.

Authors:  K A Toulis; W Hanif; P Saravanan; B H Willis; T Marshall; B Kumarendran; K Gokhale; S Ghosh; K K Cheng; P Narendran; G N Thomas; K Nirantharakumar
Journal:  Diabetes Metab       Date:  2017-03-18       Impact factor: 6.041

4.  A novel lymphocyte toxicity assay to assess drug hypersensitivity syndromes.

Authors:  M G Neuman; I M Malkiewicz; N H Shear
Journal:  Clin Biochem       Date:  2000-10       Impact factor: 3.281

5.  Sialylation of anti-histone immunoglobulin G autoantibodies determines their capabilities to participate in the clearance of late apoptotic cells.

Authors:  I Magorivska; L E Muñoz; C Janko; T Dumych; J Rech; G Schett; F Nimmerjahn; R Bilyy; M Herrmann
Journal:  Clin Exp Immunol       Date:  2016-01-27       Impact factor: 4.330

Review 6.  The physiology of glucagon-like peptide 1.

Authors:  Jens Juul Holst
Journal:  Physiol Rev       Date:  2007-10       Impact factor: 37.312

Review 7.  Drug induced liver injury with analysis of alternative causes as confounding variables.

Authors:  Rolf Teschke; Gaby Danan
Journal:  Br J Clin Pharmacol       Date:  2018-05-14       Impact factor: 4.335

8.  Liraglutide-induced autoimmune hepatitis.

Authors:  Emily Kern; Lisa B VanWagner; Guang-Yu Yang; Mary E Rinella
Journal:  JAMA Intern Med       Date:  2014-06       Impact factor: 21.873

Review 9.  RUCAM in Drug and Herb Induced Liver Injury: The Update.

Authors:  Gaby Danan; Rolf Teschke
Journal:  Int J Mol Sci       Date:  2015-12-24       Impact factor: 5.923

10.  Superior HbA1c control with the fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese individuals with type 2 diabetes in a phase 3, double-blind, randomized trial.

Authors:  Hirotaka Watada; Shizuka Kaneko; Mitsuhisa Komatsu; Bue Ross Agner; Tomoyuki Nishida; Mattis Ranthe; Jiro Nakamura
Journal:  Diabetes Obes Metab       Date:  2019-09-17       Impact factor: 6.577
View more
  1 in total

Review 1.  Drug-Induced Liver Injury: Highlights and Controversies in the Recent Literature.

Authors:  Joseph William Clinton; Sara Kiparizoska; Soorya Aggarwal; Stephanie Woo; William Davis; James H Lewis
Journal:  Drug Saf       Date:  2021-09-17       Impact factor: 5.606
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.